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Gonadal steroid hormones act in the brain to elicit changes in
gene expression that result in profound effects on behavior
and physiology. A variety of in vitro studies indicate that nu-
clear receptor coactivators are required for efficient tran-
scriptional activity of steroid receptors. Two nuclear receptor
coactivators, steroid receptor coactivator-1 (SRC-1) and
cAMP response element binding protein-binding protein
(CBP), have been shown to act in concert to enhance ER ac-
tivity in vitro. In the present study, we investigated the func-
tion of these important nuclear receptor coactivators in es-
trogen action in rodent brain. Reduction of SRC-1 and CBP
protein in brain disrupted ER-mediated activation of the be-
haviorally relevant progestin receptor gene. Furthermore, we
found that SRC-1 and CBP function in brain to modulate the
expression of hormone-dependent female sexual behavior.
These findings indicate that these nuclear receptor coactiva-
tors function in brain to modulate ER transcriptional activity
and the expression of hormone-dependent behavior. (Endo-
crinology 143: 436–444, 2002)
STEROID HORMONES ARE essential for growth, devel-opment, and reproduction. Many of the biological ef-
fects of steroid hormones are mediated by their respective
intracellular steroid receptors, which are members of a nu-
clear receptor superfamily of transcriptional activators (1, 2).
Disruption of hormone action during development or in
adulthood can result in devastating endocrine disorders that
have profound effects on reproductive physiology (3). While
many of these endocrine disorders are caused by mutations
in receptors or altered hormone levels, recently, some of
these disorders have been attributed to defects in nuclear
receptor coactivators (4–6), which are critical for nuclear
receptor activity. Thus, it is essential to understand the func-
tion of these nuclear receptor coactivators in reproductive
behavior and physiology.
The ovarian hormones, E2 and progesterone, act in the
brain to regulate rodent female reproductive behavior and
physiology (7–10). E2 and progesterone elicit many of their
effects on female reproduction by binding to their respective
receptors, ER and PR, in specific regions of the brain. Upon
binding hormone, steroid receptors undergo a conforma-
tional change that causes dissociation from an inactive oli-
gomeric complex composed of heat shock proteins and im-
munophilins, transforming the receptor to the active form
(11). The activated receptors then dimerize (12) and bind to
the steroid response element of steroid-target genes to alter
the rate of gene transcription (13). A classic example of a
steroid-responsive gene is the induction of the PR gene by E2
in a variety of hormone-responsive tissues, including brain
(14–17). This ER-dependent induction of PR gene expression
is thought to occur via an estrogen response element in the
promoter of the PR gene (18–20). In the brain, E2 induces PR
expression in the medial preoptic area (mPOA) and ventro-
medial nucleus of the hypothalamus (VMN) (16, 17, 21, 22),
sites known to regulate hormone-dependent reproductive
behavior (8, 21, 23–27). Moreover, E2 induction of PR in the
VMN is required for progesterone-facilitated reproductive
behavior (21).
Nuclear receptor coactivators have been shown to dra-
matically enhance the transcriptional activity of nuclear re-
ceptors in a variety of in vitro studies (28–31). As proposed
by Liu et al. (32), nuclear receptor coactivators are thought to
enhance steroid-dependent gene transcription via a two-step
mechanism in which coactivators bridge the steroid receptor
complex with the basal transcription machinery and remodel
chromatin structure through their intrinsic histone acetyl-
transferase activity (33, 34). Steroid receptor coactivator-1
(SRC-1, also known as NCoA-1), which was the first coac-
tivator of steroid receptors to be discovered, belongs to a
larger p160 family of nuclear receptor coactivators (29). This
family of coactivators also includes SRC-2 (NCoA-2/GRIP-
1/TIF-2) (35, 36) and SRC-3 (RAC3/AIB1/pCIP/ACTR/
TRAM1) (5, 37, 38). In vitro, SRC-1 enhances the transcrip-
tional activity of a variety of nuclear receptors, including ER
and  and PR, in a ligand-dependent manner (29, 39). SRC-1
is expressed in a variety of hormone-responsive tissues in-
cluding brain, uterus, prostate, and breast (40–47). SRC-1
Abbreviations: Arc, Arcuate nucleus; CBP, CREB binding protein;
CREB, cAMP response element binding protein; mPOA, medial preoptic
area; ODN, oligodeoxynucleotide; SRC-1, steroid receptor coactivator-1,
also known as NCoA-1; TBS, Tris-buffered saline; TBS-T, TBS containing
0.05% Tween-20; VMN, ventromedial nucleus of the hypothalamus.
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null mutant mice, while fertile, exhibit decreased growth of
steroid-responsive tissues, such as the uterus, prostate and
testes, compared with wild-type mice (42). Interestingly,
SRC-2 is up-regulated in these SRC-1 knockouts, suggesting
that SRC-2 may partially compensate for the loss of SRC-1 in
these mice (42). SRC-3 null mice have disrupted female re-
productive physiology, including delayed puberty and pro-
longed estrous cycles compared with their wild-type litter-
mates (48).
cAMP response element binding protein (CREB) binding
protein (CBP) was initially discovered to be a transcriptional
activator of CREB (49, 50). More recently, CBP has been
found to function as an integrator of nuclear receptors with
other cell signaling pathways (50, 51). Studies reveal that CBP
and SRC-1 function together to increase ER and PR function
and transcriptional activity in vitro (52, 53). It has been sug-
gested that SRC-1, as well as other members of the p160
family, provides a platform to recruit CBP to the coactivator
complex (31, 43).
A few recent studies have begun to investigate the role of
coactivators in hormone action in brain. SRC-1 mRNA is
expressed throughout the brain, including high levels in the
hypothalamus, hippocampus, cerebellum, thalamus, and
amygdala (40, 46, 47, 54). In addition, two isoforms of SRC-1,
SRC-1a and the truncated SRC-1e, are expressed differen-
tially in the rat brain (46). SRC-1a is found in high levels in
the hypothalamus, whereas SRC-1e predominates in areas
such as the nucleus accumbens, thalamus, and amygdala
(46). Moreover, SRC-1 has recently been shown to be critical
for hormone-dependent development of the mammalian
brain (45). Reduction of SRC-1 expression in the sexually
dimorphic nucleus of the preoptic area, by antisense oligo-
nucleotides to SRC-1 mRNA, disrupts the estrogen-depen-
dent sexual differentiation of this nucleus (45). Whereas
SRC-2 mRNA has been observed in cerebellum (55) and
whole brain (42), one in situ hybridization study has failed to
detect SRC-2 in brain (46). SRC-3 appears to be expressed in
hippocampus, cerebellum, and olfactory bulb (48). Finally,
immunocytochemical studies reveal that CBP protein is
widely expressed in brain, and is found in high levels in the
hypothalamus, preoptic area, thalamus, amygdala, hip-
pocampus, cortex, and cerebellum (56). While homozygous
knockouts for CBP die in utero, heterozygote adults have
memory deficits, suggesting CBP is required for normal
brain development (57).
In order for nuclear receptor coactivators to enhance ste-
roid receptor transcriptional activity in brain, both coactiva-
tor and receptor must be present in the same cell. Indeed,
recent studies in our lab have found that PR- and ER-
containing neurons coexpress SRC-1 and CBP in the VMN
and mPOA (58), sites known to regulate hormone-dependent
reproductive behavior (7, 8, 21, 23–27). In support of these
findings, SRC-1 and ER are coexpressed in rat mammary
tissue (41).
While much is known about the molecular mechanisms of
coactivators in hormone action in vitro, we are only begin-
ning to understand the function of these important cofactors
in hormone-dependent gene expression in brain and the
regulation of behavior (59). The present experiments tested
the hypotheses that SRC-1 and CBP are involved in ER-
mediated transactivation of the progestin receptor gene in
brain. Furthermore, we asked if these coactivators function
in specific cell populations in the brain to modulate hormone-
dependent female sexual behavior. In this report, we dem-
onstrate that decreasing expression of SRC-1 and CBP in the
VMN disrupts hormone-dependent PR gene expression in
brain and female sexual behavior.
Materials and Methods
Experimental animals
Adult female (175–200 g) and male (300–350 g) Sprague Dawley rats
from Charles River Breeding Laboratories, Inc. (Wilmington, MA) were
housed singly in a 14-h light, 10-h dark cycle, with lights off at 1000 h.
Animals were given food and water ad libitum. Female rats were anesthe-
tized with a combination of chloral hydrate (170 mg/kg) and pentobarbital
(35 mg/kg), ovariectomized, and then placed in a stereotaxic apparatus for
implantation of 28-gauge bilateral cannulae aimed just dorsal to the VMN
[anterior-posterior,3.14 mm; medial-lateral, 1.0 mm; dorsal-ventral,9.0
mm from Paxinos and Watson (60)]. This cannulae placement allowed
infusion of oligodeoxynucleotides into the VMN without destroying VMN
cell bodies or fibers. Only animals in which infusion cannulae descended
to a depth within 1 mm of the fornix, and medial to the fornix, were included
in immunocytochemical and behavioral analyses. A 1-wk recovery period
followed to allow clearing of endogenous hormones. During this week, the
animals were handled and dummy cannulae were removed and replaced
to prevent clogging of guide cannulae. All animal procedures were
approved by the Institutional Animal Care and Use Committee of the
University of Massachusetts (Amherst, MA).
Exp 1
Antisense oligodeoxynucleotide treatment. Antisense oligodeoxynucleoti-
des (Oligos Etc., Wilsonville, OR) (21-oligomer) specific to SRC-1 (5
CTG-TCC-CCA-AGG-CCA-CTC-ATG 3, targeting both SRC-1a and
SRC-1e isoforms) and CBP (5 CAG-CAA-GTT-CTC-GGC-CAT-CTT 3)
mRNA were designed to span the translation start site to prevent trans-
lation of these coactivators. Control oligodeoxynucleotides (Oligos, Etc.)
contained the same bases in scrambled sequence, and were confirmed
to not cross-hybridize with other rodent gene sequences by a Basic Local
Alignment Search Tool search of National Center for Biotechnology
Information (www.ncbi.nlm.nih.gov). The chimeric oligodeoxynucle-
otides (ODNs) used in these experiments contain limited phosphoro-
thioate linkages resulting in increased resistance to nuclease degradation
of the ODNs and increased RNase H activity, which allows for more
efficient digestion of target RNA strands. Finally, phosphorothioate-
linked antisense oligonucleotides have been reported to be stable in
rodent brain for up to 24 h (61).
One week following ovariectomy, each animal was administered one
ODN infusion at 0900 h on 3 d consecutively (d 1, 2, and 3). Each rat was
infused with both SRC-1 (1 g) and CBP (1 g) antisense ODN in 2 l
of saline to one side of the VMN and 1.0 g of each of the scrambled
control ODNs to the contralateral VMN (n 14). To determine the effect
of each coactivator alone, another group of animals was infused with
either antisense ODNs to SRC-1 (1g, n 7) or CBP (1g, n 7) mRNA
and the corresponding scrambled control ODN (1 g) infused into the
contralateral VMN. Bilateral infusions were administered simulta-
neously and cannulae left in place for 1 min after infusion to prevent
ODNs from being drawn up into the guide cannulae. To induce PR
expression, animals were injected with 17- E2 benzoate (EB; 2 g
dissolved in 0.1 ml of sesame oil, sc) on d 2 (15). Forty-eight hours
following E2 injection (d 4), animals were injected with an overdose of
an anesthetic mixture (ip, 425 mg/kg chloral hydrate and 89 mg/kg
pentobarbital) and perfused intracardially with saline for one minute,
followed by 2% acrolein in 0.1 m phosphate buffer for 14 min at a fixative
flow rate of 25 ml/min. Brains were removed and stored in 20% sucrose
solution for 48 h at 4 C and transverse sections were cut from the POA
through the hypothalamus at 40 m on a freezing microtome. Brain
sections were stored in cryoprotectant at20 C until immunocytochem-
istry was performed.
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Progestin receptor immunocytochemistry
Sections were initially rinsed in 0.05 m Tris-buffered saline (TBS),
followed by a pretreatment of 1% sodium borohydride for 10 min to
remove residual aldehydes. Tissue was then rinsed in TBS and incubated
in a solution of 1% H2O2, 20% normal goat serum, and 1% BSA in TBS
for 20 min to decrease nonspecific staining and reduce endogenous
peroxidase activity. Sections were incubated for 48 h in 1:1000 dilution
of a rabbit polyclonal primary antibody generated against the DNA
binding domain of human PR (A0098, DAKO Corp., Carpinteria, CA) in
TBS containing 0.02% sodium azide (NaN3), 1% normal goat serum, 0.1%
gelatin, and Triton-X (pH 7.6 at 4 C). Tissue was rinsed in TBS containing
NaN3, gelatin, and Triton-X before incubation in a biotinylated goat
antirabbit IgG (3 g/ml, Vector Laboratories, Inc., Burlingame, CA) in
TBS containing NaN3 and Triton X-100 and 1.5% normal goat serum for
90 min. Tissue was rinsed in TBS containing NaN3, gelatin, and Triton
X-100 followed by rinsing in TBS. Sections were then incubated for 90
min in TBS containing 1% avidin DH:biotinylated horseradish peroxi-
dase H complex (Vectastain ABC Elite Kit, Vector) followed by rinsing
in TBS. Finally, sections were exposed to 0.5% diaminobenzine with 3%
hydrogen peroxide with TBS for approximately 3 min. The sections were
rinsed in TBS and then mounted on microscope slides and coverslipped
using DePeX mounting medium (Electron Microscopy Sciences, Fort
Washington, PA).
PR-immunoreactive cells in the VMN, arcuate nucleus, and mPOA
[Plates 32, 32, and 20, respectively, as defined by Paxinos and Watson
(60)] were analyzed under 200 magnification using a Leitz Dialux 20
microscope (Leitz, Wetzler, Germany) with an MTI CCD72 camera
(Dage MTI, Michigan City, MI) connected to a Macintosh G3 computer.
The number of immunoreactive cells was quantified using the NIH
Image 1.62 program as described previously (62). Briefly, the microscope
was placed in Kohler illumination and the gain and black levels of the
camera were adjusted so that the pixel density of a blank section of the
slide measured 2–10 U and black measured 252 U. The threshold for
detection of specific immunoreactivity was determined as a function of
background. Cells were considered immunopositive at a density four
times that of the background threshold and if they were greater than 10
pixels but smaller than 200 pixels in total area.
Analysis of nuclear receptor coactivator protein expression
To determine if antisense treatment decreased SRC-1 and CBP protein
expression in the VMN, immunocytochemistry for nuclear receptor
coactivators was done using the procedure described above with the
following modifications. For immunocytochemical detection of SRC-1,
1135-H4, a mouse monoclonal primary antibody generated against
amino acids 477–947 of human SRC-1 (kindly provided by Dean Ed-
wards, University of Colorado Health Sciences Center; and Bert
O’Malley, Ming Tsai, and Sergio On˜ate, Baylor College of Medicine), and
biotinylated goat antimouse secondary antibody (Jackson Immuno-
Research Laboratories, West Grove, PA) were used. For analysis of CBP
expression, a rabbit polyclonal antibody generated against amino acids
162–176 of human CBP (PA1–847, Affinity BioReagents, Inc., Golden,
CO) was used. SRC-1- and CBP-immunoreactive cells in the VMN were
analyzed as described above.
To determine if antisense decreased CBP protein expression as de-
tected by Western blot, adult females were bilaterally infused into the
VMN with antisense to both CBP and SRC-1 mRNA (n 3) or scrambled
control (n  6) ODNs. Using a cryostat, frozen brains were sectioned at
300 m onto glass slides. The ventromedial hypothalamic area was
dissected out on a chilled surface and stored frozen until homogeniza-
tion with ice-cold lysis buffer consisting of 50 mm Tris-HCl, 1% Na-
deoxycholate, 0.25% NP-40, 150 mm NaCl, 1 mm EDTA, and protease
inhibitors (1 g/ml of aprotinin, leupeptin, and pepstatin; 1 mm phey-
nylmethylsulfonyl fluoride). Following tissue homogenization, samples
were centrifuged at 2,000 g for 30 min at 4 C. The supernatant fraction
was collected, and protein concentration determined by Bradford assay.
Briefly, protein concentration was quantified by comparing colorimetric
intensity of the reaction product from each sample (performed in trip-
licate) with a set of known protein standards. Twenty micrograms of
total protein from each rat were electrophoresed on a pre-cast SDS-
polyacrylamide gel (8–16% Tris glycine) and transferred to a polyvi-
nylidenedifluoride membrane. Membranes were washed briefly in 0.1
m TBS and blocked for 1 h in 0.1 m TBS containing 5% nonfat dry milk
with constant agitation at room temperature. Membranes were then
incubated with a rabbit polyclonal antibody generated against human
CBP peptide (PA1–847) at a dilution of 1:3000 in TBS containing 0.05%
Tween-20 (TBS-T) for 3 h at room temperature. Following washes in
TBS-T, membranes were incubated in a goat antirabbit HRP-linked
secondary antibody (1:2000, Cell Signaling Technology, Beverly, MA)
for 30 min at room temperature, and then washed in TBS-T. Immuno-
reactive bands were detected using an enhanced chemiluminescence kit
(ECL kit; New England Biolabs, Inc., Beverly, MA) and membranes
exposed to film (Hyperfilm-ECL, Amersham Pharmacia Biotech, Ar-
lington Heights, IL). Films were placed on a light box, and a digital image
was captured. The image was analyzed using the public domain NIH
Image program. Within this program, a gel plotting macro was used to
perform densitometric analysis of CBP, which integrates both the optical
density and the area of immunolabeling of each band. The numbers
represent the number of pixels in the area under the curve.
Cell death analysis
To determine whether antisense infusions damaged brain tissue in
the VMN, nissl-stained matched VMN sections were analyzed for cell
death. Pyknotic cells were counted at 1,000 magnification using a
Nikon Optiphot-2 microscope. Pyknotic cells were determined by their
condensed size and intensified staining relative to surrounding neurons
or glial cells (63). Photomicrograph of healthy and pyknotic cells were
taken under 1,000magnification with a Nikon FX-35DX 35 mm camera
with Kodak 160 Tungsten color slide film (Eastman Kodak Co., Roch-
ester, NY).
Exp 2
Female sexual behavior. Rats were ovariectomized and cannulated as
described in Exp 1. After a 1-wk recovery period, females were primed
with 2 g of EB and 44 h later with 300 g of progesterone. Four hours
later, females were tested for sexual receptivity with an intact male. Only
females that were sexually receptive, as indicated by displaying lordosis,
remained in the study. One week later, females were administered
bilateral infusions of ODNs into the VMN at 900 h on d 1, 2, and 3. One
group of females received bilateral infusions of antisense ODNs to SRC-1
and CBP mRNA (1 g of each, n  12), while a second group received
bilateral infusions of scrambled control ODNs (1 g of each control
ODN, n  9). On d 2, animals were injected with 2 g of EB. On d 4
animals were injected with 300 g of progesterone and tested 4 h later
for sexual behavior.
Females were tested for lordosis by being placed in a Plexiglas arena
(53 cm diameter) with an intact sexually experienced male. Testing was
performed under a dim red light during the dark phase of the light:dark
cycle, with each female receiving 10 mounts by the male. For each mount,
the lordosis response and rejection behaviors (kicking, biting, or fight-
ing) were recorded by two experimenters who were blind with regard
to treatment group. Each lordosis response was measured on a scale
from 0 (no dorsoflexion) to 3 (maximal dorsoflexion) (27, 64). For each
female, lordosis intensity (LI, total points scored/number of mounts)
and the lordosis quotient [(LQ, number of lordosis responses/number
of mounts)  100] were calculated. All behavior sessions were video
taped.
Statistical analysis
Cell counts of each brain area were analyzed using a two-tailed paired
t test with the statistical software program, SigmaStat (SPSS, Inc., San
Rafael, CA). For clarity in representing the decrease in cell numbers in
the within animal design, data are expressed as the ratio of PR cells
in antisense-treated VMN to PR cells in scrambled control-treated VMN
in Table 1. Analyses of Western blot data and behavioral scores were
done using two-tailed t tests. Differences were considered significant at
a probability of less than 0.05.
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Results
Exp 1: nuclear receptor coactivators modulate E2-induced
PR expression
Infusion of antisense ODNs to both SRC-1 and CBP mRNA
into one side of the VMN decreased the number of E2-
induced PR-immunoreactive cells in this nucleus compared
with the control-treated contralateral VMN (Fig. 1 and Table
1). The effect of antisense ODNs on E2-induced PR was
observed consistently in the VMN of all animals, with many
of the animals showing a decrease in the ventrolateral aspect
of the VMN (Fig. 1), a subregion thought to be important in
the regulation of progesterone-facilitated lordosis (25). In
contrast, when antisense ODNs to only SRC-1 mRNA, or
only CBP mRNA, were infused into the VMN, no differences
in PR expression were observed between scrambled control-
and antisense-treated nuclei (Table 1). Taken together, these
data suggest that both SRC-1 and CBP are important in
modulating ER-mediated activation of PR gene expression.
No differences in the number of PR-immunoreactive cells in
the VMN were observed when treated with scrambled con-
trol ODNs (260.5  59.5) or H2O (255.5  61.5), suggesting
that scrambled control ODNs had no nonspecific effect on PR
gene expression. When cannulae were placed outside the
VMN and did not meet our acceptable criteria as described
in Materials and Methods, no differences in PR expression in
the VMN were found between antisense- (81  32.6 PR-IR
cells) and scrambled control- (103  47.6, P  0.28) treated
animals. Within the animals with acceptable cannulae place-
ments, there was no correlation between cannulae placement
and degree of E2 induction of PR or reproductive behavior.
No difference in the number of E2-induced PR-immuno-
reactive cells was detected between matched sides of the
arcuate nucleus of the hypothalamus (ARC) when antisense
ODNs to both SRC-1 and CBP (148.3  21.5) or scrambled
control ODNs (147.6 20.3) were infused into the VMN (n
14), indicating that the ODNs did not diffuse into the ARC
and alter E2-induced PR gene expression in this nucleus.
Likewise, analysis of the mPOA revealed no differences in
the number of PR-immunoreactive cells between antisense-
treated (141.6 32.2) and scrambled control-treated (134.4
27.6) nuclei (n  14).
One possibility for coactivator antisense decreasing E2-
induced PR expression is that the antisense ODNs may cause
nonspecific cell death in the VMN. However, we found no
differences in the number of pyknotic cells (63) in the anti-
sense treated VMN (4.3  0.8, n  6) compared with the
scrambled control treated VMN (3.8  1.0, n  4) (Fig. 2),
indicating that a reduction in PR protein expression was not
due to increased cell death in the this brain area. These
findings are consistent with other studies that found no in-
crease in cell death in brain due to antisense ODN treatment
(65). Furthermore, in the present study tissue damage did not
appear to extend into the VMN, as infusion cannulae were
placed just dorsal to this nucleus (Fig. 3).
Immunostaining for SRC-1 was performed to confirm that
antisense treatment reduced SRC-1 protein expression. In-
fusion of the VMN with antisense ODNs to both SRC-1 and
CBP mRNA decreased the number of SRC-1 protein-express-
ing cells relative to the contralateral control-treated VMN
(Fig. 4A), confirming that antisense treatment was effective
in decreasing the target protein. While a difference in
the number of CBP-immunoreactive cells in the VMN was
not detected by immunocytochemistry (antisense-treated
VMN 104.0 39.4 CBP-IR cells vs. control-treated VMN
99.4 50.7, n 5), we did observe a difference in CBP protein
expression in the ventromedial hypothalamus as detected by
Western blot analysis. As shown in Fig. 4B, CBP protein
levels were lower in antisense-treated animals compared
with controls. These data suggest that our antisense tech-
nique was indeed effective in decreasing CBP protein ex-
pression in the ventromedial hypothalamus, an area that
contains the VMN. The inability to detect a decrease in CBP
by immunocytochemistry may be due to the difficulty in
optimizing this technique for a protein that is widely ex-
pressed in brain (56). In further support of antisense dis-
rupting SRC-1 and CBP expression in the female brain, the
present effects of coactivator antisense on gene expression
TABLE 1. Antisense to both SRC-1 and CBP mRNA reduces E2-
induced PR gene expression in the VMN
ODNs to SRC-1 and CBP ODNs to SRC-1 ODNs to CBP
0.82  0.06a 1.0  0.10 0.93  0.12
Data are presented as ratio of the number of PR-immunoreactive
cells in the antisense-treated VMN relative to the control-treated
contralateral VMN. Infusion of antisense ODNs to both SRC-1 and
CBP mRNA decreased E2-induced PR gene expression in the anti-
sense-treated side of the VMN relative to the control-treated con-
tralateral side (n 14). No differences in PR expression were observed
when antisense ODNs to SRC-1 mRNA only (n  7), or CBP mRNA
only (n  7), were infused into the VMN compared with the control-
treated contralateral side.
a P  0.05; two-tailed paired t test.
FIG. 1. Antisense ODNs to coactivator mRNA decreases
E2-induced PR gene expression in the VMN. The VMN of
a female rat treated (A) on one side with scrambled con-
trol ODNs and (B) antisense ODNs to SRC-1 and CBP
mRNA on the contralateral side. Scale bar, 50 m.
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were observed only when antisense to both SRC-1 and CBP
were used.
Exp 2: nuclear receptor coactivators influence hormone-
dependent reproductive behavior
To test the hypothesis that nuclear receptor coactivators
function in the brain to modulate hormone-dependent fe-
male reproductive behavior, we used our antisense tech-
nique to decrease coactivator expression in the behaviorally-
relevant VMN. Animals that received infusions of antisense
ODNs to both SRC-1 and CBP mRNA in the VMN had a
decrease in lordosis intensity compared with animals treated
with scrambled control ODNs (Table 2). As assessed by the
number of chamber midline crossings, there were no differ-
ences in general locomotor activity between scrambled con-
trol (15.8  1.2)- and antisense (19.9  2.2)-treated rats, sug-
gesting that a decrease in lordosis intensity by antisense
treatment was not due to differences in locomotor activity.
These data extend our findings from Exp 1 and provide
further evidence that SRC-1 and CBP influence hormone
action in the VMN. Moreover, these results suggest these
nuclear receptor coactivators function in the VMN to mod-
FIG. 2. Photomicrograph of healthy and pyknotic cells in the VMN.
A Nissl-stained section with several healthy cells (open arrows) and
one pyknotic cell (closed arrow) in the VMN of a scrambled ODN-
treated female. No differences were found in the number of pyknotic
cells between antisense- or scrambled control-treated VMN (see Re-
sults section). Scale bar, 10 m.
FIG. 3. Histology of infusion cannulae placement dorsal to the VMN.
Nissl-stained section shows that guide cannulae (gc) were implanted
so that infusion cannula tips (ict) were just dorsal to the VMN. f,
Fornix; ARC, arcuate nucleus; 3V, third ventricle; ME , median em-
inence. Scale bar, 100 m.
FIG. 4. Antisense oligodeoxynucleotides to SRC-1 and CBP mRNA
decrease nuclear receptor coactivator protein expression in the ven-
tromedial hypothalamus. A, Histogram represents immunocytochem-
ical analysis of the number of SRC-1-immunoreactive (SRC1-IR) cells
in the corresponding VMN of females treated on one side with scram-
bled control ODNs and antisense ODNs to both SRC-1 and CBP
mRNA on the contralateral side (n  4). *, P  0.02, paired t test.
B, Histogram represents Western blot analysis of the densitometric
area of CBP-immunoreactive bands in the ventromedial hypothala-
mus of females treated bilaterally with scrambled control ODNs
(n  7) and females treated bilaterally with antisense ODNs to both
SRC-1 and CBP mRNA (n  6). Inset is a photomicrograph of three
representative animals from each group showing a reduction of CBP
protein expression by antisense ODNs. *, P  0.04, t test.
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ulate the expression of hormone-dependent female repro-
ductive behavior.
We detected no effect of antisense treatment on the lor-
dosis quotient (Table 2). Our data suggest that while the
intensity of lordosis was altered by coactivator antisense
treatment, the frequency of lordosis was not changed. No
difference was detected in the rejection quotient in antisense-
treated (0.15  0.04) and control-treated (0.22  0.07) rats.
Discussion
The nuclear receptor coactivators, SRC-1 and CBP, have
been shown previously to act in concert to enhance ER and
PR transcriptional activity in vitro (52). In the present studies,
we used antisense ODNs to decrease SRC-1 and CBP protein
expression in brain to test the hypothesis that these coacti-
vators function in hormone action in an in vivo system. In-
deed, we found that SRC-1 and CBP are important in me-
diating steroid-dependent transcriptional activity in brain
and the expression of hormone-dependent reproductive be-
havior. Infusion of antisense ODNs to SRC-1 and CBP mRNA
into the VMN decreased E2-induced PR gene expression in
this behaviorally-relevant brain region (Fig. 1 and Table 1).
These findings indicate a functional role for coactivators in
hormone-dependent gene expression in the brain. No effect
on PR gene expression was observed following infusion of
antisense to either SRC-1 or CBP mRNA alone. The present
finding that antisense to SRC-1 mRNA alone was not effec-
tive in altering hormone-dependent gene expression in brain
is consistent with the fact that SRC-1 knockout mice remain
fertile (42). While it is possible that our assay was not sen-
sitive enough to detect an effect of antisense to only one
coactivator, it may be that suppression of both nuclear re-
ceptor coactivators is required to alter ER action. Thus, our
data extend previous in vitro findings (52) by providing ev-
idence that SRC-1 and CBP function together to modulate ER
activity in brain.
One limitation of the present experiments is that they do
not exclude the possibility that coactivator antisense ODNs
are affecting E2-induced PR cells indirectly by acting on cells
that lack ER. However, virtually all hypothalamic E2-
induced PR cells contain ER (66). Furthermore, neuroana-
tomical data from our lab reveal that the majority of E2-
induced PR cells in the VMN coexpress SRC-1 and/or CBP
(58). Taken together, the present findings are consistent with
the concept of coactivator antisense ODNs acting directly on
ER-containing cells in the VMN. Based on these findings, and
a variety of in vitro studies, we propose that nuclear receptor
coactivators modulate ER-mediated induction of PR gene
expression in brain. Activated ER dimers bind to an estrogen
response element on the PR gene (18, 19). SRC-1 and CBP, as
well as other coactivators, bridge the ER dimer with the basal
transcription machinery (28, 30, 31, 33, 34), and facilitate
efficient transcription of the PR gene. While it is possible that
the present CBP effects are via a steroid receptor independent
pathway, our finding that CBP antisense decreases E2-
induced PR expression only in conjunction with SRC-1 an-
tisense, and not alone, suggests that CBP is acting as a co-
activator of ER. In support, in vitro studies indicate that CBP
coactivates ER and  (51, 52, 67) and interacts with SRC-1
(51, 68), suggesting a model in which ER forms a ternary
complex with SRC-1 and CBP at target gene promoters (29,
51, 52). Finally, the activity of other transcription factors in
which CBP serves as a coactivator, such as CREB, are not
influenced by SRC-1 (29).
While in the present studies antisense ODNs to SRC-1 and
CBP mRNA decreased E2-induced PR gene expression in the
VMN, we did not expect an elimination of PR induction for
the following reasons. While many PR-containing cells in the
VMN express SRC-1 and/or CBP (58), it is important to note
that not all PR cells in this nucleus contain both SRC-1 and
CBP. Therefore, one would not expect antisense to these
coactivators to influence all E2-induced PR cells in the VMN.
In addition, it is likely that other coactivators function in
modulating ER action in brain. For example, recent studies
of SRC-3 knockout mice have implicated this coactivator in
female reproductive physiology (48). Furthermore, other
coactivators, such as TR-associated protein, receptor inter-
acting protein 140, and vitamin D receptor interacting pro-
tein, can also enhance transcriptional activity of ER  and 
in vitro (69–75). These coactivators may also function in ER
action in brain and could be up-regulated to compensate for
the reduction of SRC-1 and CBP in antisense-treated animals.
Although our antisense treatment was effective in decreasing
coactivator protein expression, as is the case with this tech-
nique (76, 77), it did not eliminate expression of the target
protein. Finally, there is likely to be a subpopulation of cells
containing E2-induced PR that use coactivator-independent
mechanisms, as has been proposed in mammary tissue (41).
Nevertheless, our data provide evidence that SRC-1 and CBP
are important in modulating ER-mediated induction of PR
gene expression in a distinct population of cells in the
behaviorally-relevant VMN.
E2-induced PR in the VMN are necessary for the expres-
sion of progesterone-facilitated sexual behavior in female
rodents (21). Exp 1 of the present study demonstrates that
SRC-1 and CBP are important in ER-mediated transactiva-
tion of PR gene expression in the behaviorally relevant VMN.
Therefore, we investigated if these nuclear receptor coacti-
vators function in the VMN to modulate the expression of
hormone-dependent reproductive behavior. Indeed, infu-
sion of antisense ODNs to both SRC-1 and CBP mRNA in the
VMN of E2- and progesterone-treated female rats decreased
the lordosis intensity when compared with rats treated with
scrambled ODNs (Table 2). These data extend our findings
from Exp 1 and provide further evidence that SRC-1 and CBP
influence hormone action in the VMN. In addition, these
TABLE 2. SRC-1 and CBP function in the VMN to modulate the









2.3  0.07 88.9  4.0
SRC-1 and CBP
Antisense ODNs
1.9  0.10a 86.7  4.0
Animals treated with bilateral infusions of antisense ODNs to both
SRC-1 and CBP mRNA (n 12) in the VMN had a decrease in lordosis
intensity compared with scrambled control ODN-treated animals
(n  9).
a P  0.01; two-tailed t test.
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results of coactivator antisense treatment on lordosis are
consistent with the concept that nuclear receptor coactivators
serve a permissive role in the expression of hormone-
dependent sexual behavior. Finally, it should be noted that
there are likely to be subpopulations of behaviorally relevant
ovarian steroid receptors that operate through coactivator-
independent pathways, and thus would not be directly in-
fluenced by our experimental design.
The present studies do not distinguish whether these be-
havioral effects are due to a decrease in coactivator function
on the activity of ER, PR, or both. One possibility, as sug-
gested by the results of Exp 1, is that antisense to SRC-1 and
CBP mRNA reduces the number of E2-induced PR, resulting
in a decrease in the behavioral responsiveness to progester-
one in the VMN. In support of this concept, similar behav-
ioral deficits are caused by decreased PR activity in brain
using antagonists (78, 79) or antisense to PR (80–82). How-
ever, while these other studies detected effects on the lordosis
quotient, the present study did not. This discrepancy may be
due to compensation by other coactivators (as described
above) and/or the difficulty in suppressing coactivator ex-
pression, which is more ubiquitous (40, 41, 44, 46) than the
temporally defined expression of PR (14, 22, 83). Another
possibility for the present effect of antisense on behavior,
although not exclusive of the first, is that PR activity is
diminished due to the decrease in coactivators, resulting in
a reduction in progesterone-facilitated behavior. Addition-
ally, the expression of other estrogen-regulated behaviorally-
relevant genes in the VMN (e.g. preproenkephalin and oxy-
tocin receptors, see Refs. 84–87) may have been affected by
coactivator antisense treatment in our experiments, and thus
altered hormone-dependent reproductive behavior. Future
experiments on the role of nuclear receptor coactivators in
hormone action in brain will need to be done to test these
various hypotheses.
Our results, that nuclear receptor coactivators function in
ER action in brain, are further supported by findings that
SRC-1 is required for the estrogen-dependent development
of the sexually dimorphic nucleus of the preoptic area and
the development of normal male sexual behavior in rats (45).
The present studies provide evidence for an integral role of
the nuclear receptor coactivators, SRC-1 and CBP, in hor-
mone-dependent gene expression in brain and the expres-
sion of behavior. Reduction of coactivator expression by
antisense ODNs decreased ER-mediated PR gene expression
in the VMN. Furthermore, we found that nuclear receptor
coactivators function in the VMN to modulate hormone-
dependent female reproductive behavior. The mechanisms
by which hormones act in a tissue-specific manner is a fun-
damental issue in steroid hormone action. Nuclear receptor
coactivator action in brain appears to be an important mech-
anism for the fine-tuning of steroid responsiveness within
individual neurons and the regulation of behavior. In future
studies, it will be critical to investigate the function of other
coactivators in the modulation of hormone action in brain
and behavior.
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